Balance Sheet
Cash Flow Statement
Net Income
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHYF) Cash from Investing Activities (2019 - 2023)

Historic Cash from Investing Activities for Innate Pharma (IPHYF) over the last 5 years, with Q2 2023 value amounting to -$267875.4.

  • Innate Pharma's Cash from Investing Activities rose 3644.52% to -$267875.4 in Q2 2023 from the same period last year, while for Jun 2023 it was -$2.0 million, marking a year-over-year increase of 8850.38%. This contributed to the annual value of $9.8 million for FY2024, which is 5570.92% down from last year.
  • Per Innate Pharma's latest filing, its Cash from Investing Activities stood at -$267875.4 for Q2 2023, which was up 3644.52% from -$421487.4 recorded in Q2 2022.
  • Innate Pharma's 5-year Cash from Investing Activities high stood at -$267875.4 for Q2 2023, and its period low was -$69.4 million during Q2 2019.
  • Moreover, its 5-year median value for Cash from Investing Activities was -$7.2 million (2020), whereas its average is -$21.2 million.
  • In the last 5 years, Innate Pharma's Cash from Investing Activities surged by 9776.96% in 2021 and then plummeted by 4169.78% in 2022.
  • Over the past 5 years, Innate Pharma's Cash from Investing Activities (Quarter) stood at -$68.8 million in 2019, then skyrocketed by 76.82% to -$15.9 million in 2020, then skyrocketed by 93.42% to -$1.0 million in 2021, then skyrocketed by 59.82% to -$421487.4 in 2022, then surged by 36.45% to -$267875.4 in 2023.
  • Its Cash from Investing Activities stands at -$267875.4 for Q2 2023, versus -$421487.4 for Q2 2022 and -$1.0 million for Q4 2021.